News
Subcutaneous zilucoplan – the end of necessary “trips” to the hospital for myasthenia gravis patients?
A study recently published in Lancet Neurology demonstrated the efficacy and safety of the subcutaneously administered complement component C5 inhibitor – zilucoplan – in the treatment of myasthenia gravis (MG). This drug has the potential to alleviate the severity of this disease and improve the quality of life of patients.
Wireless Smart Devices Monitor Health by Detecting Sounds
The human body continuously emits various forms of acoustic-mechanical signals that can provide…
Economic Burden and Loss of Quality of Life as a Consequence of Dry Eye Syndrome
Canadian authors evaluated the direct and indirect financial costs associated with dry eye syndrome…
Advances in the Treatment of Myasthenia Gravis on the Horizon
The research of new drugs for the generalized form of myasthenia gravis has made significant…
Biocompatibility of 3D Printed Materials – Their Comparison, Legislation, and Practice
Printing three-dimensional (3D) objects brings new possibilities for producing personalized…
Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice – Results from the VILP Registry
At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's…
Bimekizumab in 3rd Line Biological Treatment After Risankizumab Failure – Case Study
The possibilities of biological therapy for severe forms of psoriasis are very broad today. Achieving...
How Does Artificial Intelligence Help in Drug Development?
In recent years, technologies leveraging artificial intelligence have transitioned from potentially…
Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A…